Global Peptide Cancer Vaccine Market Size Likely to Reach at a CAGR of 27.7% By 2034

As per the Peptide Cancer Vaccine Market size analysis conducted by the CMI Team, the global Peptide Cancer Vaccine Market is expected to record a CAGR of 27.7% from 2025 to 2034. In 2025, the market size is projected to reach a valuation of USD 1.64 Billion. By 2034, the valuation is anticipated to reach USD 14.80 Billion.

Peptide Cancer Vaccine Market Overview

As per the industry experts at CMI, The global Peptide Cancer Vaccine Market is experiencing rapid growth due to the increasing number of cancer patients and the need for individualized immunotherapy, which targets only cancer cells. Companies such as Imugene, Generex Biotechnology , BrightPath Biotherapeutics, Sellas, and TapImmune are driving innovation by developing personalized cancer vaccines that stimulate exact immune responses to cancer cells.

Backed by strong R&D, clinical trials, and strategic partnerships, these firms are advancing treatments for breast, lung, and other major cancers. As governments support cancer vaccine research and AI-driven tools enhance antigen targeting, peptide vaccines are emerging as a key component of next-generation oncology care.

Peptide Cancer Vaccine Market Growth Factors and Dynamics

• Increasing Cancer Rates Worldwide: The rising incidence of cancer globally is providing momentum for new therapies, including peptide cancer vaccines. The World Health Organization (WHO) stated that cancer remains one of the leading causes of death, with approximately 9.6 million deaths recorded in 2018, and the incidence is still trending upwards at a frightening rate. To address this urgent need, Sellas Life Sciences is developing its peptide vaccine candidate, galinpepimut-S (GPS), which aims to target the Wilms Tumor 1 (WT1) protein that is often found in high amounts in various cancers. Sellas has obtained Orphan Drug Designations from the U.S. The majority of the peptide based vaccines have received regulatory approval by the FDA and EMA for many cancer indications, and it is well established that GPS has tremendous potential in cancer treatment.

• Improved Peptide Synthesis: Improved peptide synthesis technologies, including SPPS and automated peptide synthesizers, have improved the efficacy, efficiency, scalability, consistency, and cost-effectiveness of vaccine production. These technologies simplify the production process and help develop more precise peptide vaccines. The company BrightPath Biotherapeutics is using these developments for BP1209, a fully personalized neoantigen vaccine patient. BrightPath has made substantial progress in formulating BP1209 in non-clinical studies. BrightPath anticipates filing BP1209 for a clinical study soon. These events speak to an increase in opportunity for peptide vaccines in tailored cancer treatment.

• Increased R&D Investment in Immuno-oncology: The R&D funding in immuno-oncology is increasing, and this has positive implications for peptide living cancer vaccines. Both governmental and private investments into researching the immune system’s capacity for oncological treatment are increasing, thereby accelerating innovation and clinical trials. Marker Therapeutics (previously TapImmune) has emerged as a key innovator in the field, developing peptide health potency vaccines for various cancer treatments; these innovations have attracted significant funding to support a therapeutic pipeline in immunotherapy. These trends suggest an increase in the confidence in immune-based treatments. Formulated peptide vaccines for cancer therapy as forms of immunotherapy are particularly exciting.

Report Scope

Peptide Cancer Vaccine Market SWOT Analysis

• Strengths: This market is benefitting from progress in personalized medicine and immunotherapy. Peptide cancer vaccines are specific, inexpensive, relatively simple to manufacture and store, and just need to be designed to target tumor-specific antigens, controlling damage to healthy cells. The strong pipeline of research and ongoing clinical trial results improve confidence in the market. Imogene and Sellas are leading the way with regard to innovations in the field.

• Weaknesses: While peptide vaccines have promise, they typically have relatively weak immunogenicity, meaning that they often need adjuvants and other combination therapies to improve effectiveness. The ability to successfully identify correctly targeted antigens is a general weakness across all vaccines, as this ability varies from patient to patient; therefore, the outcomes can be inconsistent due to the specificity required for each targeted antigen, which may be difficult to identify in different patients. The same factors that affect vaccine development generally are also true for this market, specifically difficulties in regulatory approvals and R&D costs, which lead to reduced enthusiasm for newcomers in developing. Peptide vaccines have had a more subdued clinical success versus similar mRNA or viral vector platforms, and patient-specific situations have fewer logistical and scale prospects as well.

• Opportunities: The growing interest in personalized cancer treatment opens vast opportunities for peptide vaccines. Technological advancements in genomics, proteomics, and AI-based target prediction enhance vaccine development. Collaborations between biotech firms and research institutes are expanding globally. Emerging markets in Asia-Pacific and Latin America show increased funding and research interest. Furthermore, new cancer indications and combination therapies offer room for expansion.

• Threats: Competition from alternative immunotherapy markets will stifle market share, which faces threats from CAR-T and mRNA vaccines. Unreliable reimbursement structures and high-risk R&D will deter new entrants. The reality is that ongoing, lighter emerging intellectual property disputes or regulatory landscapes will prolong development either by delayed or incorrect approval. Patient recruitment is more difficult because the targeted population is relatively narrow. Plus, local and global politics, or economic disturbances can adversely impact supply chains and funding.

List of the prominent players in the Peptide Cancer Vaccine Market:

• Imugene
• Generex Biotechnology
• BrightPath Biotherapeutics
• Sellas
• TapImmune
• OncoTherapy Science
• VAXON Biotech
• Boston Biomedical
• Ultimovacs
• Immatics
• ISA Pharmaceuticals
• Others

We have segmented the Peptide Cancer Vaccine Market as follows:

By Type

• Multivalent Peptide Vaccine
• Peptide Cocktail Type
• Personalized Peptide Vaccine
• Peptide-Pulsed Dendritic Cancer Vaccine
• Hybrid Peptide Vaccine

By Application

• Breast Cancer
• Lung Cancer
• Melanoma
• Prostate Cancer

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America